Clinical Trial Update: An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes an open-label Phase 1/2 study evaluating ECUR-506 in male infants under 9 months with neonatal-onset Ornithine Transcarbamy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ornithine Transcarbamylase Deficiency
• Urea Cycle Disorders Inborn

Drugs mentioned

• ECUR-506

Snippet

Sponsor: iECURE, Inc. | Conditions: Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease | Phase 1, Phase 2 | Status: RECRUITING